Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study

Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study

Alopecia areata (AA) is a non-scarring tissue-specific autoimmune disorder. Many therapeutic modalities are available for the treatment of AA, but none has yet proven to be uniformly effective. Fractional carbon dioxide (FRCO 2 ) laser has been introduced as a treatment modality for AA. The objectiv...

Full description

Saved in:
Bibliographic Details
Published in:Archives of Dermatological Research Vol. 315; no. 3; pp. 505 - 511
Main Authors: Halim, Dalia Abdel, Nayer, Mariam, El-Samanoudy, Solwan Ibrahim, Raheem, Heba Mohamed Abdel, Ragab, Nanis
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-04-2023
Springer Nature B.V
Subjects:
Alopecia
Alopecia Areata - drug therapy
Baldness
Betamethasone - therapeutic use
Betamethasone Valerate - therapeutic use
Carbon dioxide
Carbon Dioxide - therapeutic use
Dermatology
Hair
Humans
Lasers
Lasers, Gas - adverse effects
Medicine
Medicine & Public Health
Original Paper
Patient satisfaction
Patients
Statistical analysis
Treatment Outcome
Betamethasone valerate
Fractional
Carbon dioxide
Laser
Alopecia areata
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Alopecia areata (AA) is a non-scarring tissue-specific autoimmune disorder. Many therapeutic modalities are available for the treatment of AA, but none has yet proven to be uniformly effective. Fractional carbon dioxide (FRCO 2 ) laser has been introduced as a treatment modality for AA. The objective is to evaluate and compare the efficacy and safety of FRCO 2 laser in treatment of AA alone or in combination with betamethasone valerate cream. 30 patients were assigned to one of the following groups, Group A FRCO 2 , Group B FRCO 2 plus betamethasone valerate cream or Group C (betamethasone valerate cream). Patients received eight laser sessions 2 weeks apart, treatment period was 4 months. A statistically significant decrease in SALT score, dystrophic hair and a statistically significant increase in terminal hair was observed in all groups. Patient satisfaction level and reduction in SALT score were significantly higher among FRCO 2 and FRCO 2 plus betamethasone valerate group. However, no statistical significant difference was found between FRCO 2 group and FRCO 2 combined with betamethasone valerate cream group. FRCO 2 laser is a safe and effective treatment modality for AA when used alone or in combination with betamethasone valerate cream. However, it was found superior to betamethasone valerate cream monotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-022-02393-5